Zevra Therapeutics Files DEF 14A for FY2023
Ticker: ZVRA · Form: DEF 14A · Filed: Apr 3, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | DEF 14A |
| Filed Date | Apr 3, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 20 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: DEF 14A, executive-compensation, corporate-governance
Related Tickers: ZEVRA
TL;DR
Zevra Therapeutics (ZEVRA) filed its DEF 14A for 2023, detailing exec pay and corporate governance. Check it out.
AI Summary
Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a DEF 14A with the SEC on April 3, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation and other corporate governance matters. The company is located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
Why It Matters
This filing provides crucial information for shareholders regarding executive compensation, potential conflicts of interest, and other governance details that can impact investor decisions and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings often contain information about executive compensation, related-party transactions, and other governance matters that can signal potential risks or opportunities for investors.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period for the DEF 14A filing.)
- 20240403 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- ZEVRA THERAPEUTICS, INC. (company) — Filer
- KEMPHARM, INC (company) — Former company name
- 1180 CELEBRATION BOULEVARD, SUITE 103 (address) — Business and mailing address
- CELEBRATION, FL 34747 (address) — Business and mailing address
FAQ
What is the primary purpose of this DEF 14A filing for Zevra Therapeutics?
The primary purpose is to provide information to shareholders regarding annual meetings, executive compensation, and other corporate governance matters, as required by SEC regulations.
When was Zevra Therapeutics formerly known as?
Zevra Therapeutics was formerly known as KEMPHARM, INC, with name changes noted on May 30, 2013, and May 7, 2008.
What is the business address of Zevra Therapeutics?
The business address is 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
What is the SIC code for Zevra Therapeutics?
The Standard Industrial Classification (SIC) code for Zevra Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What fiscal year does this DEF 14A filing cover?
This DEF 14A filing covers the fiscal year ending December 31, 2023.
Filing Stats: 4,875 words · 20 min read · ~16 pages · Grade level 12.9 · Accepted 2024-04-03 16:15:21
Filing Documents
- zvra20240303_def14a.htm (DEF 14A) — 1205KB
- proxy1pic.jpg (GRAPHIC) — 38KB
- proxy2pic.jpg (GRAPHIC) — 38KB
- yw0d_zeropage1.jpg (GRAPHIC) — 145KB
- yw0d_zeropage2.jpg (GRAPHIC) — 166KB
- 0001437749-24-010874.txt ( ) — 2935KB
- zvra-20231231.xsd (EX-101.SCH) — 10KB
- zvra-20231231_def.xml (EX-101.DEF) — 14KB
- zvra-20231231_lab.xml (EX-101.LAB) — 31KB
- zvra-20231231_pre.xml (EX-101.PRE) — 15KB
- zvra20240303_def14a_htm.xml (XML) — 141KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 DELINQUENT SECTION 16(A) REPORTS 33
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 34 DIRECTOR COMPENSATION 45 SECURITIES AUTHORIZED FOR ISSUANCE UNDER THE EQUITY COMPENSATION PLANS 48 TRANSACTIONS WITH RELATED PARTIES 49 HOUSEHOLDING OF PROXY MATERIALS 51 OTHER MATTERS 52 ANNEX A: AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN A-1
Forward-Looking Statements
Forward-Looking Statements Certain statements herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of the Company and its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The words or phrases "guidance," "believe," "expect," "anticipate," "estimates," "forecast" and similar words or expressions are intended to identify such forward-looking statements. In addition, any statements that refer to expectations or other characterizations of future events or circumstances, such as statements about our business plans, strategies and initiatives, and our corporate governance initiatives, are forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other important factors, some of which are beyond our control and are difficult to predict. These forward-looking statements are based on information currently available to us and our current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the Securities and Exchange Commission. Other unknown or unpredictable factors also could have material adverse effects on our future results, performance or achievements. In light of these risks, uncertainties, assumptions and fac